India, Aug. 14 -- Vyome Holdings Inc. is all set to commence trading on the Nasdaq Stock Market on Friday, August 15, 2025, under the ticker symbol "HIND", following a reverse merger with ReShape Lifesciences (RSLS).
Vyome is focused on developing drug products for currently unmet multifactorial inflammatory diseases like malignant fungating wounds (MFW), uveitis, and inflammatory acne.
The company's lead investigational product is VT-1953, a topical gel, which in a phase II trial has demonstrated a favorable safety profile, significantly decreased malodor and pain, and improved the quality of life (QoL) in patients with malignant fungating wounds (MFW). (Source: AACR).
googletag.cmd.push(function() { googletag.display('div-gpt-ad-156818...